Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

The FDA on Tuesday approves Ozempic, the weight loss drug made by Novo Nordisk, for the treatment of chronic kidney disease ...

Novo Nordisk's blockbuster drug is now a kidney disease fighter, threatening dialysis giants and reshaping the ...

A satirical X post saying the three major insulin manufacturers in the United States had announced 2,000%-3,000% price ...

President Donald Trump issued executive orders late Friday reviving some of his first term’s anti-abortion policies, like ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce ...

Analyst Terence Flynn of Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of ...